[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552869":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":154,"collaborators":156,"id":160,"slug":161,"hasResults":162,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":23,"eligibilityCriteria":166,"healthyVolunteers":162,"sex":167,"minAge":168,"maxAge":23,"enrollmentInfo":169,"targetDuration":23,"studyType":172,"phases":173,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":45,"whyStopped":23,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},{"fullName":5,"class":6},"Myeloid Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MT-303","EXPERIMENTAL","Participants will receive MT-303 through intravenous infusion.",[13],"Drug: MT-303",{"label":15,"type":10,"description":16,"interventionNames":17},"MT-303 + Atezolizumab + Bevacizumab","Participants will receive MT-303 in combination with Atezo\u002FBev through intravenous infusion.",[18],"Drug: MT-303 +Atezolizumab + Bevacizumab",[20,24],{"type":21,"name":9,"description":9,"armGroupLabels":22,"otherNames":23},"DRUG",[9],null,{"type":21,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"MT-303 +Atezolizumab + Bevacizumab","MT-303 in combination with Atezo\u002FBev",[15],[29],{"name":30,"affiliation":5,"role":31},"Matthew Maurer, MD","STUDY_DIRECTOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},"Project Manager","CONTACT","+61 2 8569 1400","Lucy.FrereScott@novotech-cro.com",{"name":39,"role":35,"phone":40,"phoneExt":23,"email":41},"Clinical Department","+1 617 465 1022","303clinical@myeloidtx.com",[43,60,73,86,99,111,122,133,146],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"St Vincent's Hospital","RECRUITING","Sydney","New South Wales","2010","Australia","AU",{"type":52,"coordinates":53},"Point",[54,55],151.20732,-33.86785,{"lat":55,"lon":54},[58],{"name":59,"role":35,"phone":23,"phoneExt":23,"email":23},"Hao-Wen Sim, MD",{"facility":61,"status":45,"city":62,"state":63,"zip":64,"country":49,"countryCode":50,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Integrated Clinical Oncology Network (ICON) Pty Ltd","Woolloongabba","Queensland","4102",{"type":52,"coordinates":66},[67,68],153.03655,-27.48855,{"lat":68,"lon":67},[71],{"name":72,"role":35,"phone":23,"phoneExt":23,"email":23},"Vladimir Andelkovic, MD",{"facility":74,"status":45,"city":75,"state":76,"zip":77,"country":49,"countryCode":50,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"The Alfred Hospital","Melbourne","Victoria","3004",{"type":52,"coordinates":79},[80,81],144.96332,-37.814,{"lat":81,"lon":80},[84],{"name":85,"role":35,"phone":23,"phoneExt":23,"email":23},"Stuart Roberts, MD",{"facility":87,"status":45,"city":88,"state":89,"zip":90,"country":49,"countryCode":50,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Linear Clinical Research","Murdoch","Western Australia","6150",{"type":52,"coordinates":92},[93,94],115.83757,-32.06987,{"lat":94,"lon":93},[97],{"name":98,"role":35,"phone":23,"phoneExt":23,"email":23},"Tim Humphries, MD",{"facility":100,"status":45,"city":101,"state":23,"zip":23,"country":102,"countryCode":23,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Pusan National Univesity Hospital","Busan","South Korea",{"type":52,"coordinates":104},[105,106],129.03004,35.10168,{"lat":106,"lon":105},[109],{"name":110,"role":35,"phone":23,"phoneExt":23,"email":23},"Jeong Heo, MD",{"facility":112,"status":45,"city":113,"state":23,"zip":23,"country":102,"countryCode":23,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Cha University Bundang Medical Center","Gyeonggi-do",{"type":52,"coordinates":115},[116,117],126.76917,37.58944,{"lat":117,"lon":116},[120],{"name":121,"role":35,"phone":23,"phoneExt":23,"email":23},"Hongjae Jeoon, MD",{"facility":123,"status":45,"city":124,"state":23,"zip":23,"country":102,"countryCode":23,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Seoul National University Hospital","Seoul",{"type":52,"coordinates":126},[127,128],126.9784,37.566,{"lat":128,"lon":127},[131],{"name":132,"role":35,"phone":23,"phoneExt":23,"email":23},"Yoon Jun Kim, MD",{"facility":134,"status":45,"city":135,"state":23,"zip":23,"country":136,"countryCode":137,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"National Taiwan University Hospital","Taipei","Taiwan","TW",{"type":52,"coordinates":139},[140,141],121.52639,25.05306,{"lat":141,"lon":140},[144],{"name":145,"role":35,"phone":23,"phoneExt":23,"email":23},"Chih-hung Hsu",{"facility":147,"status":45,"city":135,"state":23,"zip":23,"country":136,"countryCode":137,"cosmosGeoPoint":148,"geoPoint":150,"contacts":151},"Taipei Tzu Chi Hospital",{"type":52,"coordinates":149},[140,141],{"lat":141,"lon":140},[152],{"name":153,"role":35,"phone":23,"phoneExt":23,"email":23},"Her-shyong Shiah",{"type":155,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[157],{"name":158,"class":159},"CREATE Medicines","UNKNOWN","100552869","phase-1-a-study-of-mt-303-in-adults-with-advanced-or-metastatic-gpc3-expressing-cancers-including-hcc-100552869",false,"NCT06478693","A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC","A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma","Inclusion Criteria\n\n* Aged 18 years or older\n* Histological diagnosis of advanced\u002Frecurrent or metastatic and\u002For unresectable HCC. \\[Note: participants with other tumor types expressing GPC3 may be eligible for Module 1 pending a discussion with the Medical Monitor. Only participants with HCC are eligible for Module 2.\n* Measurable lesion per RECIST 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1\n* Child-Pugh score: Class A\n* Adequate organ function\n\nGeneral Exclusion Criteria\n\n* Known active CNS metastasis and\u002For carcinomatous meningitis.\n* Any acute illness including active infection\n* History of liver transplantation or on waiting list\n* Participants with untreated or incompletely treated varices with bleeding or high risk for bleeding\n* Uncontrolled pleural effusion, pericardial effusion, or ascites\n* History of symptomatic congestive heart failure\n* History of chronic or recurrent (within the last year) severe autoimmune or immune mediated disease requiring steroids or other immune-suppressive treatments.\n\nAdditional Module 2 Exclusion Criteria:\n\n* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.\n* Significant cardiovascular disease\n* History of severe hypersensitivity to atezolizumab and\u002For bevacizumab.\n* History of idiopathic pulmonary fibrosis\n* Prior history of hypertensive crisis or hypertensive encephalopathy.","ALL","18 Years",{"count":170,"type":171},70,"ESTIMATED","INTERVENTIONAL",[174],"PHASE1","This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo\u002FBev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.",[177],"Hepatocellular Carcinoma",[179,180,181,182,183],"Liver Cancer","Hepatocellular Carcinoma (HCC)","Glypican-3","Chimeric antigen receptor","CAR-M","2025-12-11",{"date":186,"type":187},"2025-12-18","ACTUAL",{"date":189,"type":187},"2024-07-01",{"date":191,"type":171},"2028-05-31",{"name":5,"class":6},9]